You are viewing the site in preview mode
Skip to main content
|
Ideal according to consensus criteria, n (%)
|
26 (57.8)
|
|
Prostate volume, median (IQR)
|
35 (27–46)
|
|
Location of treatment (combined treatment fields for n = 5 with 2 HIFU treatments)
|
|
Hemi-gland unilateral
| |
|
Hemi-gland with extension across midline or into SV
|
16
|
|
Hemi-gland anterior
|
7
|
|
Hemi-gland posterior
|
1
|
|
Quadrant (e.g. unilateral posterior)
|
1
|
|
Focal ablation (eg posterior right basal segment)
|
13
|
|
Subtotal (extended hemi-ablation, sparing lateral aspect of contralateral side)
|
6
|
|
1
|
|
Number of HIFU treatments
|
|
1
|
37
|
|
2
|
8
|
|
Known ‘insignificant’ cancer left untreated at HIFU
|
|
Yes
|
21 (47.7)
|
|
No
|
23 (52.3)
|
|
Type of biopsy pre-HIFU:
|
|
TTMB TP 5 mm Mapping + MRI-Targeted (if targets)
|
24 (53.3)
|
|
12–20 core TRUS + MR-targeted (if targets)
|
17 (37.8)
|
|
Targeted alone
|
3 (6.7)
|
|
Not documented
|
1 (2.2)
|
